Key result
Stellate ganglion block successfully controls refractory angina symptoms in a single patient.
Why the study?
Chronic refractory angina pectoris affects a large population with significant morbidity, and treatment options to improve quality of life are needed.
Does stellate ganglion block improve symptom control in a patient with refractory angina pectoris?
Case Report (n=1)
Does stellate ganglion block improve symptom control in a patient with refractory angina pectoris?
Stellate ganglion block may provide effective symptom control for patients with refractory angina pectoris.
Answers are grounded in this paper and cite their sources.
May support stellate ganglion block for refractory angina symptom control; hypothesis-generating and requires prospective validation before wider use.
Chronic refractory angina pectoris (AP) affects 600,000 to 1,800,000 Americans, with approximately 50,000 new cases annually. A recent study revealed long-term mortality of refractory AP to be lower than previously reported, with >70% of patients living >9 years. Treating AP can improve quality of life. We describe a patient with refractory AP who underwent a successful stellate ganglion block for symptom control.
No takes yet. Share an insight, caveat, or question.
Lo et al. (2018) conducted a case report in refractory angina pectoris (n=1). stellate ganglion block was evaluated on symptom control. Stellate ganglion block was successfully used for symptom control in a patient with refractory angina pectoris.
Synapse has enriched 10 related papers. Consider them for comparative context: